Pfizer Company Profile (NYSE:PFE)

About Pfizer

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira's One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: PFE
  • CUSIP: 71708110
Key Metrics:
  • Previous Close: $34.26
  • 50 Day Moving Average: $32.47
  • 200 Day Moving Average: $32.92
  • 52-Week Range: $28.74 - $37.39
  • Trailing P/E Ratio: 29.21
  • Foreward P/E Ratio: 12.28
  • P/E Growth: 2.13
  • Market Cap: $207.90B
  • Outstanding Shares: 6,068,354,000
  • Beta: 0.94
  • Net Margins: 13.50%
  • Return on Equity: 23.18%
  • Return on Assets: 8.60%
  • Debt-to-Equity Ratio: 0.48%
  • Current Ratio: 1.11%
  • Quick Ratio: 0.89%
Additional Links:
Companies Related to Pfizer:

Analyst Ratings

Consensus Ratings for Pfizer (NYSE:PFE) (?)
Ratings Breakdown: 11 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.48)
Consensus Price Target: $37.59 (9.73% upside)

Analysts' Ratings History for Pfizer (NYSE:PFE)
DateFirmActionRatingPrice TargetDetails
2/17/2017Jefferies Group LLCSet Price TargetNeutral$34.00View Rating Details
2/17/2017Berenberg BankSet Price TargetNeutral$39.00View Rating Details
2/16/2017Deutsche Bank AGReiterated RatingBuy$40.00View Rating Details
2/2/2017Morningstar, Inc.Reiterated RatingBuyView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00View Rating Details
1/30/2017BMO Capital MarketsReiterated RatingMarket Perform$33.00View Rating Details
1/24/2017Sanford C. BernsteinSet Price TargetBuy$35.00View Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00View Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$36.00View Rating Details
12/20/2016Credit Suisse GroupReiterated RatingBuy$38.00View Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralView Rating Details
11/29/2016Barclays PLCUpgradeEqual Weight -> Overweight$38.00View Rating Details
11/7/2016Bank of America CorpReiterated RatingBuy$40.00 -> $36.00View Rating Details
11/2/2016ArgusDowngradeBuy -> HoldView Rating Details
8/3/2016J P Morgan Chase & CoSet Price TargetBuy$40.00View Rating Details
8/3/2016Citigroup Inc.Reiterated RatingNeutral$37.00View Rating Details
5/17/2016Morgan StanleyReiterated RatingHold$36.00View Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00View Rating Details
5/4/2016Societe GeneraleSet Price TargetNeutral$34.00View Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70View Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
2/16/2016SunTrust Banks, Inc.Lower Price TargetNeutral$37.00 -> $33.00View Rating Details
1/26/2016Nord/LBReiterated RatingBuyView Rating Details
12/2/2015Cowen and CompanyReiterated RatingBuy$43.00View Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Pfizer (NYSE:PFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfizer (NYSE:PFE)
Current Year EPS Consensus Estimate: $2.56 EPS
Next Year EPS Consensus Estimate: $2.79 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.54$0.56$0.55
Q2 20164$0.56$0.63$0.61
Q3 20163$0.61$0.63$0.62
Q4 20162$0.50$0.50$0.50
Q1 20171$0.67$0.67$0.67
Q2 20171$0.60$0.60$0.60
Q3 20171$0.62$0.62$0.62
Q4 20171$0.56$0.56$0.56
(Data provided by Zacks Investment Research)


Current Dividend Information for Pfizer (NYSE:PFE)
Annual Dividend:$1.28
Dividend Yield:3.74%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:110.35% (Based on Trailing 12 Months of Earnings)
50.00% (Based on Current Year Consensus EPS Estimate)
45.88% (Based on Next Year Consensus EPS Estimate)
Track Record:7 Years of Consecutive Dividend Growth

Dividend History for Pfizer (NYSE:PFE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Pfizer (NYSE:PFE)
Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 69.53%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Pfizer (NYSE:PFE)
News IconThe Technical Case for and Against Pfizer Inc. (PFE) - The USA Commerce (NYSE:PFE) - February 25 at 1:17 AM
News IconPfizer Inc. (PFE), General Electric Company (GE) Stock Eyes Ahead of Earnings - The USA Commerce (NYSE:PFE) - February 25 at 1:17 AM
News IconForward Earnings Estimate of Pfizer, Inc.(PFE) - Highland Mirror (NYSE:PFE) - February 25 at 1:17 AM logoPfizer Inc. -- Moody's assigns A1 to Pfizer's notes; stable outlook (NYSE:PFE) - February 24 at 8:16 PM logoPfizer Prices $1,065,000,000 Debt Offering (NYSE:PFE) - February 24 at 8:16 PM logoPfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections (NYSE:PFE) - February 24 at 8:16 PM logoPfizer subpoenaed in U.S. over patient assistance plans (NYSE:PFE) - February 24 at 8:16 PM logoPharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs (NYSE:PFE) - February 24 at 8:32 AM
News IconThe Ashburton Jersey Ltd Invests $1726000 in Pfizer, Inc. (PFE) (NYSE:PFE) - February 24 at 12:20 AM
News IconPfizer Files 8K - Changes Executive Management (NYSE:PFE) - February 23 at 7:18 PM logoRonald E. Blaylock Elected to Pfizer’s Board of Directors (NYSE:PFE) - February 23 at 7:18 PM logoPFIZER INC Files SEC form 10-K, Annual Report (NYSE:PFE) - February 23 at 7:18 PM logoPFIZER INC Files SEC form 8-K, Financial Statements and Exhibits (NYSE:PFE) - February 23 at 7:18 PM logoDow Jones Leads Market Gains on Thursday (NYSE:PFE) - February 23 at 7:18 PM logoManufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR ... - Insider Monkey (blog) (NYSE:PFE) - February 23 at 12:18 AM logoViagra maker Pfizer cites poor performance for stock de-listing (NYSE:PFE) - February 22 at 7:18 PM
News IconPfizer Inc. (PFE) Invest For Attractive Valuation And The 4% Dividend Yield (NYSE:PFE) - February 22 at 5:06 PM
News IconWhy Investors remained confident on Advanced Micro Devices, Inc. (AMD), Pfizer Inc. (PFE)? - StockNewsJournal (NYSE:PFE) - February 22 at 9:15 AM
News IconThe Way Analysts See Pfizer Inc. (PFE) - Post Analyst (NYSE:PFE) - February 22 at 9:15 AM
News IconPfizer Inc. (PFE) : How Do the Technicals Stack Up? - The USA Commerce (NYSE:PFE) - February 22 at 9:15 AM logoWorld's Biggest Drugmaker Quits London and Swiss Listings (NYSE:PFE) - February 22 at 9:15 AM logoMerck and Co.’s Segment-Wise Revenues for 4Q16 (NYSE:PFE) - February 22 at 9:15 AM
News IconThe APG Asset Management NV Boosts Position in Pfizer, Inc. (PFE) (NYSE:PFE) - February 21 at 5:42 PM
News IconCornercap Investment Counsel Inc. Boosts Position in Pfizer, Inc. (PFE) (NYSE:PFE) - February 21 at 5:42 PM logoPfizer (PFE) BLA for Inotuzumab Ozogamicin Accepted by FDA (NYSE:PFE) - February 21 at 5:42 PM
News IconStock on Analyst Radar: Pfizer Inc (NYSE:PFE) (NYSE:PFE) - February 21 at 5:42 PM
News IconNorthstar Group Inc. Sells 128 Shares of Pfizer, Inc. (PFE) (NYSE:PFE) - February 21 at 5:42 PM logoPfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration (NYSE:PFE) - February 21 at 5:42 PM logoBoeing, GE and Oracle CEOs Support Border Adjustment Tax in Letter to Congress (NYSE:PFE) - February 21 at 5:42 PM logoBoeing, Pfizer And Others Band Together To Ask Congress For More Taxes (NYSE:PFE) - February 21 at 2:10 PM logoGE, Boeing, CAT, Pfizer among those continuing to stump for border tax (NYSE:PFE) - February 21 at 11:07 AM logoBetter Buy: Pfizer Inc. vs. Merck & Co. Inc. (NYSE:PFE) - February 21 at 9:16 AM logoA Billionaire Recently Bought Pfizer Stock -- and So Did I (NYSE:PFE) - February 19 at 7:48 AM
News IconElite Wealth Management LLC Invests $164000 in Pfizer, Inc. (PFE) (NYSE:PFE) - February 18 at 6:20 PM
News IconPfizer Inc. (NYSE:PFE) report top-line results from ORAL Strategy (NYSE:PFE) - February 18 at 6:20 PM
News IconPfizer Inc. (NYSE:PFE) PT Suggests Stock Is Worth Around $37.48 (NYSE:PFE) - February 18 at 6:20 PM logoBetter Buy: Gilead Sciences, Inc. vs. Pfizer Inc. (NYSE:PFE) - February 18 at 6:20 PM
News IconWhy Investors remained confident on MGM Resorts International (MGM), Pfizer Inc. (PFE)? - StockNewsJournal (NYSE:PFE) - February 18 at 11:38 AM
News IconNew Data in Crohns Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADEa (NYSE:PFE) - February 17 at 4:51 PM logoPfizer : New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a (NYSE:PFE) - February 17 at 4:51 PM logoPfizer (PFE) Says Data in CD Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADE (NYSE:PFE) - February 17 at 4:51 PM logoNew Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a (NYSE:PFE) - February 17 at 4:51 PM logo12:01 pm Pfizer and Celltrion Healthcare announce their trial for patients with moderate-to-severe Crohn's disease met its primary end point demonstrating that, at six weeks, INFLECTRA was similar to REMICADE (NYSE:PFE) - February 17 at 4:51 PM logoAstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink (NYSE:PFE) - February 17 at 4:51 PM
News IconLooking at the Tea Leaves for Pfizer Inc. (PFE) - The USA Commerce (NYSE:PFE) - February 17 at 8:05 AM logoPharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ (NYSE:PFE) - February 17 at 8:05 AM logo8:00 am Pfizer announces top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ (NYSE:PFE) - February 16 at 11:47 PM logoBullish Two Hundred Day Moving Average Cross - PFE (NYSE:PFE) - February 16 at 6:47 PM logoBullish Two Hundred Day Moving Average Cross - PFE (NYSE:PFE) - February 16 at 6:47 PM logoPfizer (PFE) Announces Top-Line Results from Trial of XELJANZ Compared to Humira (NYSE:PFE) - February 16 at 6:47 PM


What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 12th. Investors of record on Friday, February 3rd will be given a dividend of $0.32 per share on Wednesday, March 1st. This represents a $1.28 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Wednesday, February 1st. This is a boost from Pfizer's previous quarterly dividend of $0.30.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

21 analysts have issued 12-month price objectives for Pfizer's shares. Their forecasts range from $33.00 to $53.00. On average, they expect Pfizer's stock price to reach $37.59 in the next year.

When will Pfizer announce their earnings?

Pfizer is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What are analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • According to Zacks Investment Research, "Pfizer has been working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. While the Hospira acquisition significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal strengthened its cancer franchise by adding Xtandi to its portfolio. Pfizer’s new products like Ibrance should do well and drive revenues in 2017 while cost-savings and share buybacks should boost earnings. Pfizer’s shares surpassed that of large-cap pharma industry in the past one year. The company has a positive record of earnings surprises in recent quarters. Investor focus will remain on the stock as Pfizer has several key pipeline milestones in 2017. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. Estimates have declined slightly ahead of its Q4 earnings release." (1/25/2017)

  • Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Who owns Pfizer stock?

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.29%), Barrow Hanley Mewhinney & Strauss LLC (0.75%), Franklin Resources Inc. (0.72%), Dimensional Fund Advisors LP (0.66%), FMR LLC (0.36%) and FIL Ltd (0.31%). Company insiders that own Pfizer stock include Albert Bourla, Anthony J Maddaluna, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc and Sally Susman.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nokota Management LP, Barrow Hanley Mewhinney & Strauss LLC, Thornburg Investment Management Inc., Nicholas Co. Inc. WI, Janus Capital Management LLC, Artemis Investment Management LLP and FIL Ltd. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Anthony J Maddaluna, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten and Sally Susman.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State Street Corp, Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Appaloosa LP, FMR LLC, I.G. Investment Management LTD. and Marshall Wace LLP.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pfizer stock cost?

One share of Pfizer stock can currently be purchased for approximately $34.26.

Pfizer (NYSE:PFE) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Earnings History Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Dividend History Chart

Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Last Updated on 2/25/2017 by Staff